A single-domain antibody targeting human and cynomolgus pd-l1 cross-binding and uses thereof

By developing a single-domain antibody that cross-binds with PD-L1 in humans and cynomolgus monkeys, the problems of poor penetration and low efficacy of existing PD-L1 inhibitors have been solved. This antibody achieves specific binding and efficient blocking of PD-L1 target proteins, making it suitable for the diagnosis and treatment of PD-L1 positive tumors.

CN121405810BActive Publication Date: 2026-04-10CAPITAL UNIVERSITY OF MEDICAL SCIENCES
2 Cites 0 Cited by

Patent Information

Application Number
CN202511982839.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-12-26
Publication Date
2026-04-10
Estimated Expiration
2045-12-26

AI Technical Summary

Technical Problem

Existing PD-L1 inhibitors are mostly macromolecular drugs with poor tissue penetration, making it difficult to effectively penetrate deep into solid tumors. They also have limited efficacy in tumor treatment and may cause immune-related adverse reactions. There is a lack of cross-binding antibodies that can simultaneously target human and cynomolgus monkey PD-L1.

Method used

Develop single-domain antibodies that target and cross-bind with PD-L1 in humans and cynomolgus monkeys, containing specific complementarity-determining regions (CDRs) and framework regions (FRs) amino acid sequences for tumor diagnosis, treatment, and prognosis, with high binding capacity and cross-species binding ability.

Benefits of technology

It achieves specific binding to the PD-L1 target protein, and the partial single-domain antibody blocking effect is superior to atezolizumab. It is suitable for the diagnosis and treatment of PD-L1 positive tumors, simplifies preclinical safety assessment, and avoids the development of species-specific alternative antibodies.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting human and cynomolgus monkey PD-L1 cross-binding and application thereof. The single-domain antibody has specificity against human and cynomolgus monkey PD-L1, and shows strong binding efficiency in the binding detection with a PD-L1 target protein or a PD-L1 overexpression cell. In the detection of blocking PD-1 / PD-L1 function, part of the single-domain antibodies even show a blocking effect significantly better than Atezolizumab, which confirms that the single-domain antibody prepared by the present application can be used for the diagnosis, treatment and prognosis detection of PD-L1 positive tumors. Meanwhile, the single-domain antibody has cross-binding ability across species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need to develop species-specific alternative antibodies, so as to achieve "one target with double effect".
Need to check novelty before this filing date? Find Prior Art